Vical received US approval for the first ever cancer vaccine. The HCC interviewed the CEO of Vical (VICL), Vijay Samant, about their leading vaccines in development for CMV, melanoma, bird flu, influenza, and a gene therapy for angiogenesis to treat peripheral vascular disease.
The Healthcare Channel on http://thehcc.tv/
No comments:
Post a Comment